Jens Ebentheuer

Kassel, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Accurate Detection of α-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort.

Accurate Detection of α-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: October 11, 2022

Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.

Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: June 18, 2022

Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale in Two Independent Cohorts with Early Parkinson's Disease.

Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale in Two Independent Cohorts with Early Parkinson's Disease.

Journal: Journal of Parkinson's disease

Published: November 01, 2021

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: November 20, 2017

Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.

Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.

Journal: CNS drugs

Published: November 16, 2017

Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease: Data from the DeNoPa Cohort.

Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease: Data from the DeNoPa Cohort.

Journal: Movement disorders clinical practice

Published: January 08, 2017

Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease.

Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease.

Journal: Parkinsonism & related disorders

Published: January 08, 2016

Monitoring of 30 marker candidates in early Parkinson disease as progression markers.

Monitoring of 30 marker candidates in early Parkinson disease as progression markers.

Journal: Neurology

Published: July 08, 2015

Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy.

Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: January 22, 2015

Cutaneous neuropathy in Parkinson's disease: a window into brain pathology.

Cutaneous neuropathy in Parkinson's disease: a window into brain pathology.

Journal: Acta neuropathologica

Published: January 10, 2014

Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort.

Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort.

Journal: Neurology

Published: September 03, 2013

Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects.

Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects.

Journal: Neuroscience letters

Published: July 10, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026